Skip to main content
Clinical Trials/NCT01894854
NCT01894854
Completed
N/A

Evaluation of the Furlong Evolution Uncemented Hip Prosthesis With Special Emphasize on the Use of Collared Design or Not. A Prospective, Randomized Study Evaluated by RadioStereometric Analysis (RSA) and DXA.

Region Skane1 site in 1 country50 target enrollmentOctober 1, 2012

Overview

Phase
N/A
Intervention
Not specified
Conditions
Hip Replacement in Osteoarthritis Patients
Sponsor
Region Skane
Enrollment
50
Locations
1
Primary Endpoint
Radiostereometric Analysis (RSA)
Status
Completed
Last Updated
10 months ago

Overview

Brief Summary

The aim of this study is to further investigate the clinical and radiological importance of design changes in cementless hip prosthesis. The investigators have earlier evaluated the classical Furlong HAC total hip prosthesis and a first design change Furlong Active. Now a further development, Furlong Evolution, is to be evaluated. This prosthesis, furthermore, comes with and without a collar, and the investigators are going to randomize between the two. The investigators hypothesize that the new design will be easier to implant and will present equal or less migration than the older designs which would imply a favourable outcome in the long term. The investigators further hypothesize that the collar play no major part for the long term migration and bone remodelling.

We will now do a 10 year follow up of the patients including RSA, DXA and PROMS

Registry
clinicaltrials.gov
Start Date
October 1, 2012
End Date
March 1, 2025
Last Updated
10 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Gunnar Flivik

Associate professor, MD PhD

Region Skane

Eligibility Criteria

Inclusion Criteria

  • Primary osteoarthritis of the hip necessitating primary hip replacement
  • A femur considered suitable for uncemented fixation of the stem
  • Biological age \<75 years old at the inclusion time of the study.

Exclusion Criteria

  • Rheumatoid arthritis
  • Malignant disease
  • Severe osteoporosis
  • Earlier fracture or operation in the hip to be operated on
  • Peroperative fracture
  • Ongoing corticosteroid (oral) or immunosuppressive medication
  • Personal disorders (dementia, alcohol or drug abuse etc) suspected of making completion of the trial uncertain.

Outcomes

Primary Outcomes

Radiostereometric Analysis (RSA)

Time Frame: The first postoperative day, 14 days, 3 months, 1, 2, 5 and 10 years

This will measure the change in migration (translation and rotation around the x-, y-, and z-axis of the hip) over time. The migration pattern the first 2 years can predict the long term outcome.

Secondary Outcomes

  • Dual-energy X-ray absorptiometry (DXA)(14 days postoperatively and after 1, 5 and 10 years)
  • General health questionnaire(Preoperatively (3-4 weeks) and 1, 2, 5 and 10 years postoperatively)
  • Hip specific health questionnaire(Preoperatively (3-4 weeks) and 1, 2, 5 and 10 years postoperatively)

Study Sites (1)

Loading locations...

Similar Trials